Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Doing some DD on LATCH with Chat because I’ve be

Message Board Public Reply | Private Reply | Keep | Replies (4)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155579
(Total Views: 703)
Posted On: 02/22/2025 9:42:05 AM
Avatar
Posted By: Riztheinvestor
Re: My69z #150360
Doing some DD on LATCH with Chat because I’ve been thinking it could be announced before summer.

“You’re absolutely right to hone in on the LATCH study—it’s a pivotal piece of CytoDyn’s HIV cure puzzle, and it is intended for humans! I’ll clarify its status, assess the likelihood of an imminent announcement, and explore what it could mean for CytoDyn’s future ). Let’s dig in with the latest info and some critical reasoning.
LATCH Study: Human Trial Confirmation
The LATCH study—Leronlimab in Allogenic Transplant to Cure HIV—is indeed a human clinical trial, not just a preclinical effort. CytoDyn’s December 2024 shareholder letter explicitly states they’re partnering with amfAR (American Foundation for AIDS Research) to sponsor this study, which “will use leronlimab to protect CCR5+ donor immune cells from HIV infection while aiming for a cure in the setting of bone marrow transplantation provided to an HIV+ recipient.” This builds on:
• Preclinical Roots: OHSU’s work (e.g., NIH Grant 5R01AI129703) showed Leronlimab mimics a CCR5Δ32/Δ32 donor in primates, a concept proven in human cures like the Berlin and London patients.
• Human Intent: The letter emphasizes a clinical focus, and amfAR’s involvement—known for human cure research—confirms it’s not just monkeys this time. Plus, a German team’s interest in replicating LATCH in Berlin after their heterozygous CCR5 cure success further signals a human trial framework.
So, yes, LATCH is CytoDyn’s first explicit step into testing Leronlimab as a cure in humans, likely a Phase I or I/II trial given its exploratory nature.
Could They Announce It Soon?
As of February 22, 2025, here’s why an announcement (e.g., FDA clearance or trial initiation) might be plausible soon—and why it might not:
Reasons It Could Happen Soon
1 Momentum from 2024:
◦ The December 2024 letter says LATCH was “previously announced,” suggesting planning was advanced by late last year. With Max Lataillade onboard since June 2024, his regulatory expertise (from ViiV and BMS) could’ve fast-tracked FDA submission.
◦ The OHSU Gates grant (February 2025) for reservoir analysis could provide supporting data, nudging LATCH toward clearance.
2 Lataillade’s Dual Role:
◦ As Gates’ Head of HIV Drug Development, he’s got influence to align resources. If he’s pushing LATCH as a Gates priority, an announcement could tie into the Foundation’s 2025 agenda, possibly Q2 or Q3.
3 External Interest:
◦ German researchers requesting to run a parallel LATCH study (per the letter) adds urgency. CytoDyn’s “taking steps to make this a reality” suggests active progress, potentially prompting a public update.
4 Typical Timelines:
◦ If CytoDyn submitted an Investigational New Drug (IND) application in late 2024, FDA review takes ~30 days. A January 2025 submission could mean clearance by March/April 2025—ripe for a spring announcement.



(15)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565


Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program

⸻

Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us